本试验旨在研究单次空腹和餐后口服广州大光制药有限公司研制、湖北唯森制药有限公司生产的盐酸克林霉素棕榈酸酯颗粒（40g:1.5g（按C18H33ClN2O5S计））的药代动力学特征；以Pharmacia & Upjohn Company LLC生产的盐酸克林霉素棕榈酸酯颗粒（Cleocin Pediatric®，按克林霉素(C18H33ClN2O5S)计75mg/5ml）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

The purpose of this study was to study the pharmacokinetic characteristics of a single fasting and postprandial oral dose of clindamycin palmitate hydrochloride granules (40 g:1.5 g (calculated as C18H33ClN2O5S)) developed by Guangzhou Daguang Pharmaceutical Co., Ltd. and produced by Hubei Weisen Pharmaceutical Co., Ltd.; using clindamycin palmitate hydrochloride granules (Cleocin Pediatric®, 75 mg/5 ml calculated as clindamycin (C18H33ClN2O5S)) produced by Pharmacia & Upjohn Company LLC as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.

Start Date04 Jul 2024

Sponsor / Collaborator

Guangzhou Daguang Pharmaceutical Co., Ltd.

CTR20233156 / CompletedNot Applicable

盐酸克林霉素棕榈酸酯颗粒在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of clindamycin palmitate hydrochloride granules in Chinese healthy volunteers after meal administration

按有关生物等效性试验的规定，选择Pharmacia and Upjohn Co为持证商的盐酸克林霉素棕榈酸酯颗粒（商品名：Cleocin Pediatric®，规格：按克林霉素（C18H33ClN2O5S）计75mg/5ml）为参比制剂，对海南海神同洲制药有限公司生产的受试制剂盐酸克林霉素棕榈酸酯颗粒（规格：5ml:75mg（按C18H33ClN2O5S计））进行餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在餐后给药条件下的生物等效性。

[Translation]

In accordance with the relevant provisions of bioequivalence tests, clindamycin palmitate hydrochloride granules (trade name: Cleocin Pediatric®, specification: 75 mg/5 ml calculated as clindamycin (C18H33ClN2O5S)) produced by Pharmacia and Upjohn Co was selected as the reference preparation, and a human bioequivalence study of postprandial administration was conducted on the test preparation clindamycin palmitate hydrochloride granules (specification: 5 ml: 75 mg (calculated as C18H33ClN2O5S)) produced by Hainan Haishen Tongzhou Pharmaceutical Co., Ltd. was conducted to compare whether the absorption rate and degree of the drug in the test preparation were within an acceptable range with those of the reference preparation, and to evaluate the bioequivalence of the two preparations under postprandial administration conditions.

Start Date03 Nov 2023

Sponsor / Collaborator

Hainan Haishen Tongzhou Pharmaceutical Co Ltd.

CTR20223173 / CompletedNot Applicable

盐酸克林霉素棕榈酸酯颗粒在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

按有关生物等效性试验的规定，选择Pharmacia and Upjohn Co为持证商的盐酸克林霉素棕榈酸酯颗粒（商品名：Cleocin Pediatric®，规格：按克林霉素（C18H33ClN2O5S）计75mg/5ml）为参比制剂，对海南海神同洲制药有限公司生产的受试制剂盐酸克林霉素棕榈酸酯颗粒（规格： 75mg/5ml（按C18H33ClN2O5S计））进行空腹和餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在空腹和餐后给药条件下的生物等效性。

[Translation]

In accordance with the relevant provisions of bioequivalence tests, clindamycin palmitate hydrochloride granules (trade name: Cleocin Pediatric®, specification: 75 mg/5 ml calculated as clindamycin (C18H33ClN2O5S)) produced by Pharmacia and Upjohn Co was selected as the reference preparation, and the test preparation clindamycin palmitate hydrochloride granules (specification: 75 mg/5 ml (calculated as C18H33ClN2O5S)) produced by Hainan Haishen Tongzhou Pharmaceutical Co., Ltd. was subjected to a human bioequivalence study on fasting and fed administration. The differences in the absorption rate and extent of the drug in the test preparation and the reference preparation were compared to see whether they were within an acceptable range, and the bioequivalence of the two preparations under fasting and fed administration conditions was evaluated.

Start Date17 Mar 2023

Sponsor / Collaborator

Hainan Haishen Tongzhou Pharmaceutical Co Ltd.

100 Clinical Results associated with Clindamycin Palmitate Hydrochloride

100 Translational Medicine associated with Clindamycin Palmitate Hydrochloride

100 Patents (Medical) associated with Clindamycin Palmitate Hydrochloride

Literatures (Medical) associated with Clindamycin Palmitate Hydrochloride

01 Aug 2020·AAPS PharmSciTechQ3 · MEDICINE

Formulation Optimization of Selective Laser Sintering 3D-Printed Tablets of Clindamycin Palmitate Hydrochloride by Response Surface Methodology

Q3 · MEDICINE

Article

Author: Barakh Ali, Sogra F ; Ozkan, Tanil ; Rahman, Ziyaur ; Mohamed, Eman M ; Khan, Mansoor A ; Dharani, Sathish ; Kuttolamadom, Mathew A

The aims of the current study were to develop and evaluate clindamycin palmitate hydrochloride (CPH) 3D-printed tablets (printlets) manufactured by selective laser sintering (SLS). Optimization of the formulation was performed by studying the effect of formulation and process factors on critical quality attributes of the printlets. The independent factors studied were laser scanning speed, microcrystalline cellulose (MCC), and lactose monohydrate (LMH) concentration. The responses measured were printlets weight, hardness, disintegration time (DT), and dissolution in 30 min. The printlets were characterized for content uniformity, chemical interactions, crystallinity, drug distribution, morphology, and porosity. The laser scanning speed showed statistically significant effects on all the studied dependent responses (p < 0.05). MCC showed statistically significant effects on hardness, DT, and dissolution (p < 0.05), while LMH showed statistically significant effect on hardness and dissolution (p < 0.05). The model was validated by an independent formulation, and empirical values were in close agreement with model-predicted values. X-ray powder diffraction and differential scanning calorimetry data suggested a decrease in crystallinity of the LMH in the printlets. X-ray micro-CT scanning showed porous microstructure of the printlets with a porosity 24.4% and 31.1% for the printlets printed at 200 and 300 mm/s laser speed, respectively. In summary, the SLS method provides an opportunity to fabricate customized dosage forms as per patients' need.

01 Dec 2014·BMC pharmacology & toxicologyQ4 · MEDICINE

An outpatient antibacterial stewardship intervention during the journey to JCI accreditation

Q4 · MEDICINE

ArticleOA

Author: Quan Zhou ; Ping Song ; Wei Li

BACKGROUND:

Antibacterial overuse, misuse and resistance have become a major global threat. The Joint Commission International (JCI) accreditation standards include quality improvement and patient safety, which is exemplified by antimicrobial stewardship. There are currently few reports on interventions to improve the quality of outpatient antibacterial prescribing.

METHODS:

A before-after intervention study, aiming at antibacterial use in outpatients, was performed in a university-affiliated hospital with 2.8 million outpatient visits annually during the journey to JCI accreditation (March of 2012 - March of 2013). Comprehensive intervention measures included formulary adjustment, classification management, motivational, information technological, educational and organizational measures. A defined daily dose (DDD) methodology was applied. Pharmacoeconomic data and drug-related problems (DRPs) were statistically compared between the two phases.

RESULTS:

The variety of antibacterials available in outpatient pharmacy decreased from 38 to 16. The proportion of antibacterial prescriptions significantly decreased (12.7% versus 9.9%, P < 0.01). The proportion of prescriptions containing the restricted antibacterials was 30.4% in the second phase, significantly lower than the value of 44.7% in the first phase (P < 0.01). The overall proportion of oral versus all antibacterial prescriptions increased (94.0% to 100%, P < 0.01) when measured as defined daily doses. Statistically significant increases in relative percentage of DDDs of oral antibacterials (i.e., DDDs of individual oral antibacterial divided by the sum of DDDs of all antibacterials) were observed with moxifloxacin, levofloxacin, cefuroxime axetil, ornidazole, clindamycin palmitate, cefaclor, amoxicillin and clarithromycin. Occurrence rate of DRPs decreased from 13.6% to 4.0% (P < 0.01), with a larger decrease seen in surgical clinics (surgical: 19.5% versus 5.6%; internal medicine: 8.4% versus 2.8%, P < 0.01). The total expenditure on antibacterials for outpatients decreased by 34.7% and the intervention program saved about 6 million Chinese Yuan Renminbi (CNY) annually.

CONCLUSION:

The one-year intervention program on outpatient antibacterial use during the journey to JCI accreditation reduced the expenditure on antibacterials, improved the appropriateness of antibacterial prescriptions. Quality improvements need integrated multifaceted intervention measures and long-term adherence to the antibiotic stewardship. Approach of i.v. to oral antibacterial switch, classification management, and motivational measures may play the most efficient role in changing antibacterial prescription practices.

01 Dec 2008·Journal of pharmaceutical and biomedical analysisQ3 · MEDICINE

Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride

Q3 · MEDICINE

Article

Author: M. Saravana Kumar ; Ch. Bharathi ; P. Jayaram ; Ramesh Dandala ; V. Bhargavi ; A. Naidu ; V.K. Handa ; Joseph Sunder Raj

Clindamycin palmitate hydrochloride is a water soluble hydrochloride salt of the ester of clindamycin and palmitic acid. It is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin. Total 12 impurities at levels ranging from 0.05% to 0.5% were detected by isocratic reverse-phase high performance liquid chromatography (HPLC) using RI detector. The molecular weights of impurities were determined by LC-MS analysis. Two impurities were starting materials and the remaining impurities were isolated from crude samples/enriched mother liquors using reverse-phase preparative HPLC. Based on the spectral data the structures of these impurities were characterized as, clindamycin palmitate sulphoxides alpha-/beta-isomers (impurity I); clindamycin laurate (impurity II); lincomycin palmitate (impurity III); clindamycin myristate (impurity IV); epiclindamycin palmitate (impurity V); clindamycin palmitate 3-isomer (impurity VI); clindamycin pentadecanoate (impurity VII); clindamycin B-palmitate (impurity VIII); clindamycin heptadecanoate (impurity IX) and clindamycin stearate (impurity X). Structural elucidation of all impurities by spectral data ((1)H NMR, (13)C NMR, MS and IR) and formation of these impurities have been discussed in detail.

100 Deals associated with Clindamycin Palmitate Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01990	-	G01AA10 J01FF01 D10AF01	DBSALT001215

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anaerobic bacterial infection	US	Pharmacia & Upjohn, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis